The embattled Canadian drug maker — which has been hit with stinging criticism from politicians for its big price hikes, and is subject to a related Congressional investigation — is now the target of a probe by the Securities Exchange Commission (SEC).
Valeant announced on Monday that it is being investigated for its links to drug distribution company, Philidor Rx Services. Sources also told the Wall Street Journal that the company may be facing scrutiny for improper financial bookkeeping.
Valeant announced in October that it was cutting ties with Philidor after reports that the distributor had changed doctors' orders to overbill insurers.
Continue Reading for Free
Register and gain access to:
- Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
